Atrasentan: all 21 studies that test it
Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.
- A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA NephropathyNot yet recruitingNCT07850752Phase 3
- Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)Not yet recruitingNCT07820995Phase 4
- Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgANRecruitingNCT07498335Phase 3
- Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA NephropathyCompletedNCT05834738Phase 2Results posted
- Atrasentan Spermatogenesis and Testicular FunctionCompletedNCT02118714Phase 2Results posted
- Study Of Diabetic Nephropathy With AtrasentanTerminatedNCT01858532Phase 3Results posted
- Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary AdenocarcinomaTerminatedNCT00653328Phase 2Results posted
- S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone TherapyCompletedNCT00134056Phase 3Results posted
- Atrasentan in Patients With Proteinuric Glomerular DiseasesActive, not recruitingNCT04573920Phase 2
- Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Phase 3
- A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With NephropathyCompletedNCT01399580Phase 2
- Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) InhibitorCompletedNCT01356849Phase 2
- Correlation of Endothelial Function and Early Coronary Artery Disease in HumansCompletedNCT00271492Phase 3
- Atrasentan and Zometa for Men With Prostate Cancer Metastatic to BoneCompletedNCT00181558Phase 2
- A Long Term Safety Study With AtrasentanCompletedNCT00127478Phase 2/3
- Atrasentan in Treating Patients With Prostate CancerCompletedNCT00046943Phase 3
- Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney CancerCompletedNCT00039429Phase 2
- Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical FailureCompletedNCT00038662Phase 2
- Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate CancerCompletedNCT00036556Phase 3
- A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate CancerCompletedNCT00036543Phase 3
- Atrasentan in Treating Patients With Progressive or Recurrent Malignant GliomaCompletedNCT00017264Phase 1